Hostname: page-component-758b78586c-dtt57 Total loading time: 0 Render date: 2023-11-30T07:11:23.031Z Has data issue: false Feature Flags: { "corePageComponentGetUserInfoFromSharedSession": true, "coreDisableEcommerce": false, "useRatesEcommerce": true } hasContentIssue false

Tardive Dyskinesia and Skin Pigmentation

Published online by Cambridge University Press:  29 January 2018

Jambur Ananth
University of California, Los Angeles and Director, Psychopharmacology Unit, Harbor-UCLA Medical Center, Dept of Psychiatry, 1000 W. Carson Street, Torrance, CA 90509, USA
Ramzy Yassa
McGill University and Psychiatrist, Douglas Hospital Centre


Within the past 15 years, it has become clear that the continuing administration of neuroleptics can produce several long term side effects, the two most important being tardive dyskinesia (TD) and skin pigmentation. In mental hospital surveys, the proportion of patients with TD has been described as about 30 to 40 per cent. At this point, there is no recognized treatment although some cases improve if the drug is discontinued (Jeste et al, 1979). In addition, TD may increase mortality (Mehta et al, 1978).

Research Article
Copyright © Royal College of Psychiatrists, 1982 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


Abnormal Involuntary Movement Scale (AIMS), Washington, DC, Alcohol, Drug Abuse and Mental Health Administration, Department of Health, Education and Welfare, 1974.Google Scholar
Ananth, J., Ban, T. A., Lehmann, H. E. & Rizvi, R. A. (1972) A survey of phenothiazine-induced skin pigmentation. Indian Journal of Psychiatry, 14, 7680.Google Scholar
Forrest, I. S., Kosek, J. C., Aber, R. C. & Serra, M. T. (1970) Rabbit as a model for chlorpromazine-induced hyperpigmentation of the skin. Biochemical Pharmacology, 19, 849–52.Google Scholar
Greiner, A. C. & Nicholson, G. A. (1964) Pigment deposition in viscera associated with prolonged chlorpromazine therapy. Canadian Medical Association Journal, 91127.Google Scholar
Jeste, D. V., Potion, S. G., Sinha, S., Feder, S. L. & Wyatt, R. J. (1979) Tardive dyskinesia: reversible and persistent. Archives of General Psychiatry, 36, 585–90.Google Scholar
Mehta, D., Mallya, A. & Volavka, J. (1978) Mortality of patients with tardive dyskinesia. American Journal of Psychiatry, 135, 371–2.Google Scholar
Perry, T. L., Culling, C. F. A., Berry, K. & Hansen, S. (1974) 7-hydroxychlorpromazine: potential toxic metabolite in psychiatric patients. Science, 146, 81–3.Google Scholar
See also American Journal of Psychiatry (1981), 138, 1618.Google Scholar
Submit a response


No eLetters have been published for this article.